DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Schneeweiss A, Ettl J, Lüftner D. et al.
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer – Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Breast 2020;
54: 88-95
We do not assume any responsibility for the contents of the web pages of other providers.